Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up

Autor: Akif Selim Yavuz, Ugur Ozbek, Mustafa Pehlivan, Güray Saydam, Mehmet Sönmez, Rıdvan Ali, Leylagül Kaynar, Zafer Baslar, Demet Aydin, Osman Ilhan, Simten Dagdas, Ibrahim C. Haznedaroglu, Olga Meltem Akay, Birol Guvenc, Orhan Ayyildiz, Ilkiz M. Dag, Bülent Ündar, Gulnur Akin
Přispěvatelé: Çukurova Üniversitesi, Ege Üniversitesi, İç Hastalıkları, Dicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıklar Ana Bilim Dalı, Ayyıldız, Mehmet Orhan, Acibadem University Dspace
Jazyk: angličtina
Rok vydání: 2018
Předmět:
0301 basic medicine
Adult
Male
medicine.medical_specialty
Blast Crisis
Turkey
Tyrosine kinase inhibitor
Molecular response
03 medical and health sciences
0302 clinical medicine
tyrosine kinase inhibitor
chronic myeloid leukemia
Internal medicine
Leukemia
Myelogenous
Chronic
BCR-ABL Positive
hemic and lymphatic diseases
medicine
Clinical endpoint
Humans
Philadelphia Chromosome
nilotinib
Aged
Philadelphia Chromosome Positive
Hematology
business.industry
Chronic myeloid leukemia
ComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKS
Myeloid leukemia
molecular response
Middle Aged
Nilotinib
BCR-ABL1
Rate of increase
ComputingMilieux_MANAGEMENTOFCOMPUTINGANDINFORMATIONSYSTEMS
030104 developmental biology
Pyrimidines
ComputingMethodologies_PATTERNRECOGNITION
Tolerability
030220 oncology & carcinogenesis
Female
InformationSystems_MISCELLANEOUS
business
medicine.drug
Follow-Up Studies
Popis: WOS: 000448137100007
PubMed ID: 29486663
Objectives: This report presents final results (24 months of follow-up) from the first prospective, national study of frontline nilotinib in chronic myeloid leukemia (CML) patients in Turkey. Methods: Patients with newly diagnosed Philadelphia chromosome-positive CML in chronic phase (CML-CP; N = 112) received nilotinib 300 mg twice daily. The primary endpoint, which was the cumulative rate of major molecular response (MMR; BCR-ABL1
Novartis Pharmaceuticals CorporationNovartis
This work was supported by the Novartis Pharmaceuticals Corporation.
Databáze: OpenAIRE
Externí odkaz: